Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Dec:54:121-126.
doi: 10.1016/j.breast.2020.09.004. Epub 2020 Sep 16.

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)

Min Ho Park  1 , Soo Jung Lee  2 , Woo Chul Noh  3 , Chang Wan Jeon  4 , Seok Won Lee  5 , Gil Soo Son  6 , Byung-In Moon  7 , Jin Sun Lee  8 , Sung Soo Kang  9 , Young Jin Suh  10 , Geumhee Gwak  11 , Tae Hyun Kim  12 , Young Bum Yoo  13 , Hyun-Ah Kim  3 , Min Young Kim  14 , Ju Yeon Kim  14 , Joon Jeong  15
Affiliations
Multicenter Study

A nationwide, multicenter retrospective study on the effectiveness and safety of eribulin in Korean breast cancer patients (REMARK)

Min Ho Park et al. Breast. 2020 Dec.

Abstract

Purpose: Approval of eribulin for metastatic breast cancer was based on data primarily from Western patients, and there is a paucity of data on the effectiveness and safety of eribulin for Asian patients. To determine the effectiveness and safety of eribulin in Korean women with breast cancer in a real-world setting, we conducted a nationwide, multicenter, retrospective study.

Methods: Patients with locally advanced or metastatic breast cancer who were treated with eribulin in 14 centers throughout Korea were included in this study. Eribulin was generally administered at a dose of 1.23 mg/m2 (equivalent to 1.4 mg/m2 eribulin mesylate) by intravenous infusion for 2-5 min, or as a diluted solution, on Days 1 and 8 of every 21-day cycle. The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included median PFS, overall survival (OS), time-to-treatment failure (TTF), tumor response rate, and incidence of hematologic treatment-emergent adverse events (TEAEs).

Results: The safety and full analysis populations included 398 and 360 (38 had no efficacy data) patients, respectively. The PFS rate at 6 months was 37.8%. Median PFS, OS, and TTF were 134, 631, and 120 days, respectively. Objective response rate, clinical benefit rate, and disease control rate were 18.1%, 50.6%, and 49.4%, respectively. Hematologic TEAEs were reported in 65.1% of patients; neutropenia (56.8%) and anemia (11.3%) were most common.

Conclusion: Real-world effectiveness and safety of eribulin in Korean breast cancer patients were consistent with previous reports; no new safety concerns were identified.

Keywords: Breast cancer; Eribulin mesylate; Korean patients; Retrospective study.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest MYK and JYK are employees of Eisai Korea Inc. All other authors declare no conflict of interest.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Kaplan–Meier plots are shown for a) progression-free survival, b) overall survival c) time-to-treatment failure; full analysis set. CI, confidence interval; OS, overall survival; PD, progressive disease; PFS, progression-free survival; TTF, time-to-treatment failure.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Kweon S.S. Updates on cancer epidemiology in Korea. Chonnam Med J. 2018;54:90–100. doi: 10.4068/cmj.2018.54.2.90. 2018. - DOI - PMC - PubMed
    1. Bray F., McCarron P., Parkin D.M. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res. 2004;6:229–239. doi: 10.1186/bcr932. - DOI - PMC - PubMed
    1. Peart O. Metastatic breast cancer. Radiol Technol. 2017;88:519M–539M. - PubMed
    1. Jordan M.A., Kamath K., Manna T., Okouneva T., Miller H.P., Davis C., Littlefield B.A., Wilson L. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Canc Therapeut. 2005;4:1086–1095. doi: 10.1158/1535-7163.MCT-04-0345. - DOI - PubMed